Company intelligence / Profile preview
Bright Angel Therapeutics
Toronto, Ontario, Canadabrightangeltherapeutics.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Bright Angel Therapeutics has not yet reported clinical results as it remains in the pre-clinical stage. The company’s lead program targets Hsp90 to overcome antifungal resistance, with the goal of enhancing efficacy across all major classes of antifungals and preventing resistance emergence. Their approach leverages advanced computational design to create fungal-selective compounds.
No clinical data available yet.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Schrödinger (co-founder, technology partner)adMare BioInnovations (investor/partner)Lumira Ventures (investor/board representation)Viva BioInnovator/Viva Biotech Holdings(investor/partner)
Beyond the preview
Go deeper on Bright Angel Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bright Angel Therapeutics.